‘Mounjaro may shift the Type 2 diabetes treatment paradigm'
By Son, Hyung-Min | translator Kim, Jung-Ju
24.04.11 17:17:33
가나다라
0
[DP Interview] Thomas Forst, Chief Medical Officer at CRS Clinical Research Services, Germany
Dual GIP/GLP-1 receptor co-agonist Mounjaro demonstrates blood glucose reduction effect
Obesity rate among diabetes patients high..." Mounjaro will provide significant benefit with the weight loss effect confirmed in clinical trials."
▲Dr. Thomas Forst, professor of Internal Medicine and Endocrinology at the Johannes Gutenberg University in Main, Germany (Chief Medical Officer, CRS Clinical Research Services, Germany)
Mounjaro has shown the most potent effect among incretin-based therapeutic agents. Based on the dramatic effect it showed in reducing blood sugar levels and weight loss in clinical trials, we expect the drug will bring about many changes field of diabetes treatment.”
Thomas Forst, Professor of Internal Medicine and Endocrinology at the Johannes Gutenberg University in Main, Germany (Chief Medical Officer, CRS Clinical Research Services, Germany), met with Dailypharm and said Mounjaro has the potential to become a game-changer in the field of diabetes.
Developed by the global pharmaceutical giant Eli Lilly, MUNJARO is a treatment for type 2 diabetes that acts on both the glucagon
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)